112 related articles for article (PubMed ID: 25785545)
1. IBRUTinib: BRUTe force against bortezomib-resistant myeloma cells.
Xian L; Huff CA; Resar LM
Cell Cycle; 2015; 14(9):1349-50. PubMed ID: 25785545
[No Abstract] [Full Text] [Related]
2. Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Murray MY; Zaitseva L; Auger MJ; Craig JI; MacEwan DJ; Rushworth SA; Bowles KM
Cell Cycle; 2015; 14(14):2367-75. PubMed ID: 25565020
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
5. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
6. Critical role of Ca
Tomita S; Sekiguchi F; Deguchi T; Miyazaki T; Ikeda Y; Tsubota M; Yoshida S; Nguyen HD; Okada T; Toyooka N; Kawabata A
Toxicology; 2019 Feb; 413():33-39. PubMed ID: 30552955
[TBL] [Abstract][Full Text] [Related]
7. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
8. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
10. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
[TBL] [Abstract][Full Text] [Related]
11. Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.
Nikesitch N; Tao C; Lai K; Killingsworth M; Bae S; Wang M; Harrison S; Roberts TL; Ling SC
Blood Cancer J; 2016 Jun; 6(6):e432. PubMed ID: 27284736
[No Abstract] [Full Text] [Related]
12. [Proteasome inhibitors in treatment of multiple myeloma].
Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
[TBL] [Abstract][Full Text] [Related]
13. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
14. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
15. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
16. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
Walsby EJ; Pratt G; Hewamana S; Crooks PA; Burnett AK; Fegan C; Pepper C
Mol Cancer Ther; 2010 Jun; 9(6):1574-82. PubMed ID: 20515939
[TBL] [Abstract][Full Text] [Related]
17. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Yu W; Chen Y; Xiang R; Xu W; Wang Y; Tong J; Zhang N; Wu Y; Yan H
Leuk Lymphoma; 2017 Feb; 58(2):428-437. PubMed ID: 27439454
[TBL] [Abstract][Full Text] [Related]
18. To b(ortezomib) or not to be: the stroma's the thing.
Krem MM; Yan J
J Pathol; 2016 Oct; 240(2):123-5. PubMed ID: 27340009
[TBL] [Abstract][Full Text] [Related]
19. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
20. Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib.
Karademir B; Sari G; Jannuzzi AT; Musunuri S; Wicher G; Grune T; Mi J; Hacioglu-Bay H; Forsberg-Nilsson K; Bergquist J; Jung T
Sci Rep; 2018 Nov; 8(1):16318. PubMed ID: 30397214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
